Telix Pharmaceuticals
The Theranostics Specialist serves as a field-based nuclear medicine technology expert responsible for the successful adoption and utilization of Telix products across the Northeast United States. This role involves overseeing site activation initiatives, optimizing imaging workflows, and driving cross-functional collaboration to support corporate sales objectives. The position focuses on strategic onboarding of new imaging sites and ensuring high-quality imaging outcomes through protocol standardization and HCP education.
Headquarters
North Melbourne, Victoria, Australia
Company Size
201-500 employees
Founded
2015
Telix Pharmaceuticals is a global, commercial‑stage biopharmaceutical company developing diagnostic and therapeutic “theranostic” products that use targeted radiation to detect and treat cancer. It advances radiopharmaceuticals through clinical development, regulatory approval, manufacturing and commercialisation to bring imaging agents and targeted therapies to patients. Telix works with the nuclear medicine community and international partners to scale access and improve outcomes. Its stated mission is to help patients with cancer live longer with better quality lives.
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Dec 14, 2025
Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX
Nov 13, 2025
Pharma groups rush to calm investor fears over Trump’s tariff hit
Sep 26, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Telix Pharmaceuticals.
Telix Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
30% below the average for this role
The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31, 2025
Nuclear Medicine Theranostics Tech $15,000 Signing Bonus I James Cancer Center
The Ohio State University
DIVISION LEAD OF NUCLEAR MEDICINE
UChicago Medicine
Program Lead for Nuclear Medicine (Physician)
Nebraska Cancer Specialists
Nuclear Medicine Technologist
billingsclinic
Global Theranostics Clinical Marketing Specialist
Siemens Healthineers
Nuclear Medicine Technologist
Brigham and Women's Hospital